Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 475

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab

Study of benralizumab compared to placebo for treatment of patients with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab

Study on the Safety and Effectiveness of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) for Adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Phenylbutyrate

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab

Dermatitis atopic

Not recruiting

Study on Long-Term Safety of GSK1070806 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Kappa Monoclonal Antibody Against Interleukin 18

Asthma

Not recruiting

Study on the Effects of Atuliflapon in Adults with Moderate to Severe Uncontrolled Asthma

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Atuliflapon

Study on the Effectiveness and Safety of Barzolvolimab in Adults with Active Eosinophilic Esophagitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab

Sjogren's syndrome

Not recruiting

Safety Study of Efgartigimod in Adults with Primary Sjögren's Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Efgartigimod Alfa

Asthma

Not recruiting

Study on Tezepelumab for Reducing Steroid Use in Adults with Steroid-Dependent Asthma

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.